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Abstract 
Background: Injury to endothelium and glycocalyx predisposes to vascular leak, which may subsequently lead to 
increased fluid requirements and worse outcomes. In this post hoc study of the prospective multicenter observational 
Finnish Acute Kidney Injury (FINNAKI) cohort study conducted in 17 Finnish intensive care units, we studied the asso‑
ciation of Syndecan‑1 (SDC‑1), Angiopoetin‑2 (Ang‑2), soluble thrombomodulin (sTM), vascular adhesion protein‑1 
(VAP‑1) and interleukin‑6 (IL‑6) with fluid administration and balance among septic critical care patients and their 
association with development of acute kidney injury (AKI) and 90‑day mortality.
Results: SDC‑1, Ang‑2, sTM, VAP‑1 and IL‑6 levels were measured at ICU admission from 619 patients with sepsis. 
VAP‑1 decreased (p < 0.001) and IL‑6 increased (p < 0.001) with increasing amounts of administered fluid, but other 
biomarkers did not show differences according to fluid administration. In linear regression models adjusted for IL‑6, 
only VAP‑1 was significantly associated with fluid administration on day 1 (p < 0.001) and the cumulative fluid balance 
on day 5/ICU discharge (p = 0.001). Of 415 patients admitted without AKI, altogether 112 patients (27.0%) developed 
AKI > 12 h from ICU admission  (AKI>12 h). They had higher sTM levels than patients without AKI, and after multivariable 
adjustment log, sTM level was associated with  AKI>12 h with OR (95% CI) of 12.71 (2.96–54.67), p = 0.001). Ninety‑day 
non‑survivors (n = 180; 29.1%) had higher SDC‑1 and sTM levels compared to survivors. After adjustment for known 
confounders, log SDC‑1 (OR [95% CI] 2.13 [1.31–3.49], p = 0.002), log sTM (OR [95% CI] 7.35 [2.29–23.57], p < 0.001), 
and log Ang‑2 (OR [95% CI] 2.47 [1.44–4.14], p = 0.001) associated with an increased risk for 90‑day mortality. Finally, 
patients who had high levels of all three markers, namely, SDC‑1, Ang‑2 and sTM, had an adjusted OR of 5.61 (95% CI 
2.67–11.79; p < 0.001) for 90‑day mortality.
Conclusions: VAP‑1 and IL‑6 associated with fluid administration on the first ICU day. After adjusting for confounders, 
sTM was associated with development of AKI after 12 h from ICU admission. SDC‑1, Ang‑2 and sTM were indepen‑
dently associated with an increased risk for 90‑day mortality.
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Background
Endothelial cells line the luminal side of all blood ves-
sels. Glycocalyx is located on the top of the endothelium. 
It is a thin (few dozens of nanometers), complex layer 
with a framework consisting of glycoproteins and pro-
teoglycans between the endothelial cell wall and flowing 
blood [1, 2]. It plays a key role in regulation of vascular 
permeability and blood cell–vessel interactions [1–3]. In 
critical illness, the body responds to stress by initiating 
sympathoadrenal activation, which leads to the release 
of inflammatory mediators, such as interleukin-6 (IL-6), 
and damage to the endothelium and glycocalyx, resulting 
in increased vascular permeability [4–6]. Several plasma 
biomarkers may be measured as indicators of glycocalyx 
[4, 7, 8] and endothelial injury [7–11].
We hypothesized that higher plasma levels of endothe-
lial and glycocalyx biomarkers measured at intensive 
care unit (ICU) admission would indicate more severe 
endothelial and glycocalyx injury, more severe capillary 
leakage, and subsequently, higher amounts of admin-
istered fluid. Therefore, we primarily studied the asso-
ciation between glycocalyx (Syndecan-1; SDC-1) and 
endothelial injury biomarkers (Angiopoietin-2; Ang-2, 
soluble thrombomodulin; sTM, and vascular adhesion 
protein-1; VAP-1) and cytokine IL-6 (as marker of the 
severity of inflammation) and fluid administration among 
critically ill septic patients. Second, we aimed to study 
the association of these markers with acute kidney injury 
(AKI) and 90-day mortality.
Methods
This was a post hoc laboratory study of the prospective 
multicenter observational Finnish Acute Kidney Injury 
(FINNAKI) cohort study conducted in 17 Finnish inten-
sive care units in 2011–2012 [12]. The Ethics Committee 
of the Department of Surgery at the Helsinki University 
Hospital gave nationwide approval for the study (refer-
ence number: 18/13/03/02/2010) and accepted the use 
of deferred consent from the patient or next of kin with 
written informed consent obtained as soon as possible. 
The Finnish National Institute of Health and Welfare 
allowed data collection from medical records of deceased 
patients to avoid bias in the primary endpoint of the FIN-
NAKI study (incidence and outcome of AKI). The current 
laboratory study includes only patients who or whose 
next of kin gave a written informed consent.
The FINNAKI study enrolled all adult emergency ICU 
admissions to study ICUs of any length and elective post-
operative patients with an expected ICU stay longer than 
24 h [12]. Exclusion criteria are presented in Additional 
file  1: Methods section of the 1.2, page 6. The current 
study included all FINNAKI study patients who were sep-
tic at ICU admission, had fluid balance data available for 
day 1, and a blood sample taken at ICU admission. FIN-
NAKI study was observational and did not include fluid 
management protocol. Thus, all patients were treated 
according to the judgement of the treating clinician and 
the Surviving Sepsis Guidelines in place at that time [13].
Data collection
We collected data on baseline chronic illnesses, ICU 
diagnoses, severity scores, and ICU treatment. Please see 
details in Additional file 1: 1.3, page 6.
Definitions
We defined sepsis according to the American College 
of Chest Physicians/Society of Critical Care Medicine 
(ACCP/SCCM) definition [14]. Presence of AKI accord-
ing to Kidney Disease: Improving Global Outcomes 
(KDIGO) criteria [15] considering creatinine (measured 
daily), hourly urine output, and use of renal replacement 
therapy (RRT) was screened until day 5 in the ICU. As a 
baseline creatinine, we used the most recent value from 
the previous year excluding the week preceding ICU 
admission according to the KDIGO guideline [15] and if 
it was not available, we estimated it using the modifica-
tion of diet in renal disease (MDRD) equation assuming a 
GFR of 75 mL/min/1.73 m2 [16].
Outcomes
Our primary outcome was association of SDC-1, Ang-2, 
sTM, VAP-1 and IL-6 with (a) fluid administration per 
hour within the first ICU day and (b) cumulative balance 
at ICU discharge or on day 5 whichever came first. Sec-
ondarily, we evaluated the independent associations of 
these biomarkers with development of AKI and 90-day 
mortality. From the AKI analysis, we excluded patients 
who were admitted with AKI (defined as AKI diagnosis 
made within 12  h of ICU admission) to study the tem-
poral association of biomarkers and development of AKI 
[17].
Calculation of fluid administration and balance
We prospectively collected data of the total amount of 
fluids administered to the patient daily including main-
tenance and resuscitation fluids, nutrition, blood prod-
ucts, drug infusions, and correspondingly, data about 
total fluid output (urine output, drainage fluids, bleed-
ing, losses from gastrointestinal tract). A surrogate for 
evaporation (generally, 1000  mL daily for normother-
mic patients and additionally, an addition for each Cel-
cius degree of fever per hour) was included in the fluid 
losses according to clinical practice. Fluid losses were 
subtracted from administered fluid to calculate fluid 
balance. The fluid data were collected from the ICU 
electronic patient records according to local ICUs fluid 
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charting day. In most ICUs, the fluid charting day was a 
24-h period starting from noon. Thus, the first study day 
was not a 24-h period for most of the patients (for exam-
ple, if patient was admitted 8 p.m., the first fluid day was 
until next noon, altogether 16 h). Therefore, the duration 
of fluid administration and balance data collected for that 
day varied between 1 and 24 h. In the current analysis, we 
combined short fluid charting days (less than 2 h) to the 
administration and balance data of the subsequent day 1, 
and report here the administered fluid and balance nor-
malized then to the total duration of fluid charting day 
that was between 2 and 26 h. Examples of these calcula-
tions are presented in Additional file 1: 1.4 page 7.
As an additional sensitivity analysis, fluid adminis-
tration data from 44 patients from Helsinki University 
Hospital ICU were retrospectively extracted in 12-h 
blocks from the ICU data management system and were 
found to correlate well (rho 0.91, p < 0.001) with the day 
0 administrations normalized to the duration of day 0 
observation period.
Cumulative balance at ICU discharge or on day 5 (last 
data collection day) was normalized to patient weight at 
ICU admission and reported as a percentage.
Laboratory samples and analyses
Plasma samples were collected at ICU admission (0 h) in 
lithium-heparin tubes, centrifuged, aliquoted, and frozen 
in − 80  °C until analyzed between April and October in 
2017. To assess the temporal behavior of the markers, we 
analyzed sequential samples from 44 patients from Hel-
sinki University Hospital ICU taken every 12 h until 36 h 
(40 patients had full series of samples from 0 to 36  h). 
Details of the laboratory analyses are presented in Addi-
tional file 1: 1.5 page 8.
Statistical analyses
We report patients’ baseline characteristics using counts 
and percentages for categorical variables and medians 
with interquartile ranges (IQR) for continuous variables 
as data were non-normally distributed. To assess possible 
differences in patients grouped according to fluid input, 
AKI status, or survival, we compared continuous data 
using the Mann–Whitney U or Kruskal–Wallis tests and 
categorical data using the Fisher’s exact or Chi-squared 
tests, as appropriate.
We ran multivariable linear regression models exam-
ining the association between different biomarkers and 
fluid input or cumulative balance, controlling for the 
effect of interleukin-6. All biomarkers and fluid input on 
day 0 normalized to hours were log transformed. Three 
subjects were removed from the analyses due to having 
high influence (Cook’s Distance of over  4/(n − p − 1), 
where n is the number of subjects and p is the number 
of covariates). We compared sequential biomarker meas-
urements from same patients with Friedman’s test.
We used multivariable logistic regression models, 
according to general practice concerning predictive 
models in critical care [18], to study whether biomarker 
levels were independently associated with the develop-
ment of AKI after 12  h from admission  (AKI>12  h) and 
90-day mortality. We studied the effect of possible con-
founders (as listed in Table  1) in univariate models for 
development of AKI and 90-day mortality. We included 
all variables with a univariate p value less than 0.20 in 
multivariable models, however excluding variables that 
were clinically closely related (such as severity scores). 
Additionally, we adjusted for sex, as recommended [19]. 
Please see Additional file 1: 1.6 (page 8) about handling of 
missing data in regression models. Model fit was assessed 
with Hosmer–Lemeshow statistics.
To study whether a combination of biomarkers could 
identify a group of patients with especially high risk for 
 AKI>12  h and 90-day mortality [20], we built biomarker 
summary score that comprised biomarkers that were 
associated with the development of AKI and/or 90-day 
mortality in univariate models with p values less than 
0.20 [21]. We categorized the biomarker levels into ter-
tiles, and for each patient, calculated the total number of 
biomarkers (up to three) where the patient fell into the 
highest tertile. Next, we studied unadjusted and adjusted 
associations of the biomarker summary score with 
 AKI>12 h and 90-day mortality with logistic regression.
We set the significance level to 1% and considered p 
values < 0.01 as statistically significant. We conducted 
analyses with SPSS statistics 24 for Windows and SPSS 23 
for Mac.
Results
Patients
We included 619 patients admitted to the ICU with sepsis 
or septic shock (Additional file 1: Figure S1). Altogether, 
137 (22.1%) patients were admitted from operating room 
or postoperative intermediate care unit, 225 (36.3%) from 
emergency department, 197 (31.8%) from the wards and 
60 (9.7%) from another ICU or intermediate care unit. 
The most common origins of sepsis were lungs in 296 
(47.8%) and gastrointestinal tract in 156 (25.2%) patients 
(Table  1). Biomarker levels at ICU admission according 
to the presence of baseline chronic illnesses are presented 
in Additional file 1: 2.1, page 10 and Table S1.
Fluid administration, balance and biomarker levels
During the first ICU day, the patients received a median 
of 247  mL/h (IQR [173–363] mL/h) fluids. Divided 
into tertiles according to fluid administration, less 
than 201 mL/h fluid was administered in the 1st tertile, 
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Table 1 Patient characteristics
Categorical data reported as count (percentage) and continuous data as median [interquartile range, IQR]
ASO arteriosclerosis obliterans, COPD chronic obstructive pulmonal disease, ICU intensive care unit, NSAID non-steroidal anti-inflammatory drug, CNS central nervous 
system, GI gastrointestinal, SOFA sequential organ failure assessment considering all six organ systems, SAPSII Simplified Acute Physiology Score II, AKI acute kidney 
injury, RRT renal replacement therapy
a First value measured within first 6 h from ICU admission
b All AKI patients
c For details please see “Methods”
d Cumulative fluid accumulation at discharge/on day 5 during ICU stay as a percentage of body weight
Data available All patients, n = 619 90d survivors, 
n = 439 (70.9%)
Non-survivors, 
n = 180 (29.1%)
p value
Age (years) 619 66 [55 to 75] 62 [52 to 73] 73 [62 to 80] < 0.001
Sex; female 619 223 (36.0%) 154 (35.1%) 69 (38.3%) 0.462
Body mass index (kg/m2) 618 26.8 [23.6 to 30.1] 27.4 [24.1 to 30.9] 25.4 [23.0 to 27.9] < 0.001
Comorbidities
 Hypertension 616 329 (53.2%) 229 (52.4%) 100 (55.9%) 0.477
 Coronary artery disease or ASO 609 89 (14.4%) 55 (12.7%) 34 (19.3%) 0.043
 Chronic heart failure 613 71 (11.5%) 38 (8.7%) 33 (18.5%) 0.001
 COPD 612 79 (12.8%) 56 (12.9%) 23 (12.9%) > 0.999
 Chronic kidney disease (GFR < 60 mL/min/1.73 m2) 615 42 (6.8%) 23 (5.3%) 19 (10.7%) 0.021
 Diabetes 619 158 (25.5%) 121 (27.6%) 37 (20.6%) 0.084
 Baseline creatinine (µmol/L) 436 76 [61 to 92] 76 [61 to 91] 76 [62 to 98] 0.458
 Pre‑ICU chronic corticosteroid use 615 77 (12.4%) 41 (9.3%) 36 (20.0%) < 0.001
 Pre‑ICU immunosuppression 614 56 (9.0%) 36 (8.2%) 20 (11.1%) 0.279
 Pre‑ICU radiocontrast 616 122 (19.7%) 93 (21.2%) 29 (16.1%) 0.150
 Pre‑ICU aminoglycoside 618 7 (1.1%) 2 (0.5%) 5 (2.8%) 0.013
 Pre‑ICU NSAID 582 94 (15.2%) 69 (15.7%) 25 (13.9%) 0.621
 Pre‑ICU amphotericin B 616 3 (0.5%) 0 [0.0%) 3 (1.7%) 0.024
 Surgical admission 619 149 (24.1%) 115 (26.2%) 34 (18.9%) 0.062
Infection source
 CNS 619 18 (2.9%) 16 (3.6%) 2 (1.1%) 0.114
 Lung 619 296 (47.8%) 209 (47.6%) 87 (48.3%) 0.929
 GI tract 619 156 (25.2%) 108 (24.6%) 48 (26.7%) 0.611
 Urinary tract 619 46 (7.4%) 34 (7.7%) 12 (6.7%) 0.737
 Skin and soft tissue 619 55 (8.9%) 45 (10.3%) 10 (5.6%) 0.064
 Other 619 19 (3.1%) 10 (2.3%) 9 (5.0%) 0.12
 Time from hospital admission to ICU admission (h) 618 22 [9 to 59] 21 [8 to 53] 23 [11 to 74] 0.067
 First lactate (mmol/L)a 536 1.80 [1.10 to 3.31] 1.60 [1.00 to 2.87] 2.20 [1.30 to 5.75] < 0.001
 First hematocrit (%)a 575 33 [29 to 37] 33 [29 to 37] 33 [28 to 37] 0.424
 Vasopressor within first 24 h 619 438 (70.8%) 300 (68.3%) 138 (76.7%) 0.041
 SOFA score at day 1 619 8 [6 to 10] 7 [6 to 9] 10 [7 to 13] < 0.001
 SAPS II score 619 42 [33 to 54] 39 [31 to 47] 54 [41 to 68] < 0.001
 SAPS II score without age and renal components 615 24 [18 to 32] 23 [17 to 29] 29 [22 to 29] < 0.001
 AKI (any severity)b 619 316 (51.1%) 203 (46.2%) 113 (62.8%) < 0.001
 AKI stage 1 619 122 (19.7%) 89 (20.3%) 33 (18.3%) 0.657
 AKI stage 2 619 54 (8.7%) 40 (9.1%) 14 (7.8%) 0.641
 AKI stage 3 619 140 (22.6%) 74 (16.9%) 66 (36.7%) < 0.001
 RRT for AKI during ICU stay 619 101 (16.3%) 52 (11.8%) 49 (27.2%) < 0.001
 Mechanical ventilation during ICU stay 619 404 (65.3%) 261 (59.5%) 143 (79.4%) < 0.001
 Fluid input on day 0 normalized to hours (mL)c 619 247 [173 to 363] 238 [167 to 337] 285 [184 to 417] 0.003
 Cumulative balance %/weightd 579 1.06 [− 2.75 to 5.68] 0.15 [− 3.11 to 4.31] 4.13 [− 2.20 to 9.90] < 0.001
 ICU length of stay (days) 618 4 [2 to 7] 4 [2 to 6] 5 [2 to 9] 0.022
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202–314 mL/h in the 2nd tertile, and 315–2824 mL/h in 
the 3rd tertile. In all 619 patients VAP-1 levels were sig-
nificantly lower in the lowest fluid administration tertile 
(p < 0.001) and in the middle tertile (p = 0.003) compared 
to the highest tertile, and IL-6 levels higher (p < 0.001) in 
the highest fluid administration tertile compared to the 
middle or lowest tertile (Fig. 1, Table 2). SDC-1, Ang-2, 
or sTM levels did not differ between the fluid administra-
tion tertiles (Fig.  1, Table  2). Correlations between bio-
markers are presented in Additional file 1: Table S2. All 
other biomarkers showed significant correlation with 
each other except (1) VAP-1 between SDC-1, (2) Ang-2 
and sTM between IL-6. The strongest correlation was 
between SDC-1 and sTM with rho of 0.406 (p < 0.001). 
IL-6 and VAP-1 correlated negatively with each other 
(Additional file  1: Table  S2). In linear regression mod-
els adjusted for IL-6, only VAP-1 was significantly asso-
ciated with fluid administration on day 1 (ß [95% CI] 
− 0.139 [− 0.213 to − 0.064], p < 0.001) and the cumula-
tive fluid balance on day 5/ICU discharge (ß [95% CI] 
− 0.130 [− 0.209 to − 0.052], p = 0.001) (Additional file 1: 
Tables S3 and S4). In the sequential samples subanalysis 
Fig. 1 Biomarker levels at ICU admission according to fluid administration tertiles. Fluid tertile 1: < 201 mL/h. Fluid tertile 2: 202–314 mL/h. Fluid 
tertile 3: 315–2824 mL/h. Between fluid tertiles 1 and 2 IL‑6 p value < 0.001, all other biomarkers’ p values > 0.010; between fluid tertiles 1 and 3 
VAP‑1 p value < 0.001 and IL‑6 p value < 0.001, all other biomarkers’ p values > 0.010; between fluid tertiles 2 and 3 VAP‑1 p value = 0.003 and IL‑6 p 
value < 0.001, all other biomarkers’ p values > 0.010
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including 40 patients with biomarkers measured every 
12  h until 36  h available, SDC-1 values were increasing 
over time (p < 0.001), IL-6 decreased (p < 0.001), and oth-
ers did not show significant differences (Additional file 1: 
Figure S2).
Biomarkers and organ failures and severity of sepsis
Patients whose SOFA scores decreased from first ICU 
day to ICU day 3 (n = 491) had significantly lower SDC-1 
(p = 0.003) and IL-6 (p = 0.001) levels at ICU admis-
sion compared to those with worsening or stable SOFA 
scores (n = 127). Other biomarkers did not correlate with 
changes in SOFA scores.
Biomarkers and AKI
Altogether, 316 (51.1%) patients had AKI. Of them, 189 
(59.8%) were diagnosed based on creatinine criterion 
only, 69 (21.8%) based on urine output criterion only, 28 
(8.9%) had both creatinine and urine output criteria posi-
tive, and in 30 (9.5%) patients commenced RRT before 
fulfilling other criteria. Of AKI patients, 204 (64.6%) were 
admitted with AKI (AKI diagnosed 0–12  h from ICU 
admission), whereas 112 (35.4%) were diagnosed more 
than 12  h from ICU admission. Of these ,112  AKI>12  h 
patients 59 (52.7%) had stage 1, 16 (14.3%) had stage 2, 
and 37 (33.0%) had stage 3 AKI according to the KDIGO 
criteria. All other biomarkers except VAP-1 were signifi-
cantly higher in all AKI patients compared to non-AKI 
patients (Additional file  1: Table  S5). Among  AKI>12  h 
patients SDC-1 and sTM were significantly higher com-
pared to non-AKI patients (Table 3). After adjusting for 
possible confounders and IL-6 levels, sTM was signifi-
cantly associated with  AKI>12  h (Table  4). Patients with 
the maximum biomarker summary score of 3 had an OR 
of 4.24 (95% CI 1.64–10.96, p = 0.003) for the develop-
ment of AKI as compared to patients with the minimum 
biomarker summary score of 0 (Table 4).
90-day mortality
By day 90, 180 (29.1%) patients were deceased. Non-sur-
vivors had higher SDC-1 and sTM levels than survivors 
(Table 5). After adjusting for multiple confounders, SDC-
1, Ang2, and sTM were independently associated with an 
increased risk for 90-day mortality (Table 6). Altogether 
65 patients had the maximum score of 3 in the biomarker 
summary score, and 35 (53.8%) of them were deceased by 
day 90. As compared to patients with the minimum bio-
marker summary score of 0, patients with the maximum 
score had the adjusted odds of OR 5.61 (95% CI 2.67–
11.79, p < 0.001) for 90-day mortality (Table 6).
Discussion
We found VAP-1 and IL-6 to be associated with the 
amount of administered fluid on the first ICU treatment 
day and other fluid balance-related variables; however, 
the other investigated markers did not differ according 
Table 2 Biomarker levels and fluid administration
IQR interquartile range
Biomarker level (ng/mL) at 0 h 
(median [IQR])
Fluid administration
1st tertile, n = 205 (4–201 mL/h) 2nd tertile, n = 206 
(202–314 mL/h)
3rd tertile, n = 208 
(315–2824 mL/h)
p value
Syndecan‑1 105.70 [56.65–205.20] 109.05 [64.93–194.25] 114.45 [64.08–231.85] 0.276
Angiopoietin‑2 6.10 [3.40–11.64] 6.97 [3.63–11.98] 5.92 [3.06–13.31] 0.669
Soluble thrombomodulin 5.03 [3.94–6.93] 5.50 [4.18–7.07] 5.53 [3.91–7.72] 0.282
Vascular adhesion protein‑1 279.00 [195.50–395.50] 244.50 [170.75–355.25] 214.50 [148.00–305.00] < 0.001
Interleukin‑6 0.22 [0.07–1.00] 0.49 [0.16–0.36] 3.17 [0.45–19.51] < 0.001
Table 3 Biomarker levels in all patients and according to development of acute kidney injury
AKI > 12 h; AKI diagnosed over 12 h from ICU admission to day 5 or ICU discharge, if earlier
Biomarker level (ng/mL) at 0 h 
(median [IQR])
All patients (n = 619) No AKI (n = 303) AKI > 12 h (n = 112) p value
Syndecan‑1 109.00 [62.30–215.40] 91.40 [55.30–157.30] 125.25 [67.60–232.68] 0.004
Angiopoietin‑2 6.31 [3.39–12.13] 5.53 [2.99–9.92] 7.44 [4.29–13.22] 0.028
Soluble Thrombomodulin 5.30 [4.02–7.13] 4.61 [3.69–5.97] 5.84 [4.37–7.94] < 0.001
Vascular adhesion protein‑1 241.00 [171.00–340.00] 255.00 [177.00–356.00] 241.50 [170.75–340.00] 0.889
Interleukin‑6 0.57 [0.14–4.74] 0.36 [0.12–3.06] 0.83 [0.17–5.10] 0.011
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to fluid administration. Only sTM remained associated 
with the development of AKI after adjusting for known 
confounders. Finally, Ang-2, SDC-1, and sTM were asso-
ciated with an increased risk for 90-day mortality, also 
after adjustments. Our results demonstrate that injury to 
glycocalyx and endothelium present at ICU admission is 
associated with an increased risk for AKI and mortality.
We observed roughly comparable plasma biomarker 
levels to previous studies [8, 22, 23]. Previously, Ang-2 
has been shown to correlate with the first 6-h balance, 
but not with the 24-h balance [24]. Our results corrob-
orate this finding. However, we did not find significant 
differences in SDC-1 levels in terms of fluid administra-
tion or balance, in contrast with a previous study that 
found SDC-1 to be associated with fluid balance over 
the first 24 h [25]. That study measured SDC-1 levels on 
the second ICU day, whereas we obtained samples right 
after ICU admission. A novel finding in our study was the 
association of higher IL-6 and lower VAP-1 levels with 
higher amount of received fluids. As more severely ill 
patients have higher IL-6 levels [26], and typically receive 
also more fluids [27], the finding regarding IL-6 was to be 
expected. The finding regarding VAP-1 is surprising, as 
one would have expected higher VAP-1 levels with higher 
Table 4 Unadjusted and  adjusted single and  multivariable biomarker logistic regression models for  the  development 
of acute kidney injury
Hosmer–Lemeshow test non-significant in all analyses
AKI acute kidney injury, IL-6 interleukin-6
a Adjusted for log-transformed interleukin-6 value at ICU admission
b Adjusted for age, sex, body mass index, pre-existing chronic kidney disease, pre-existing diabetes mellitus, presence of urinary tract infection, presence of 
skin or soft tissue infection, Simplified Acute Physiology Score (SAPS) II without points for age and renal components, need for vasoactive medication within first 
24 h, first lactate in ICU, log-transformed interleukin-6 value at ICU admission. Total number of patients in the model was 415. bIncluding Angiopoietin-2, soluble 
thrombomodulin and Syndecan-1
c An example of the interpretation of the OR of log-transformed biomarkers: the OR for development for AKI for Log Angiopoietin-2 is 2.66, so when untransformed 
Angiopoietin-2 levels grow by a factor of 10, the odds for AKI increase by a factor of 2.66
Single biomarker models
Biomarker Unadjusted OR (95% CI) p value IL-6  adjusteda OR (95% CI) p value Multivariable 
 adjustedb OR (95% 
CI)
p value
Log Angiopoietin‑2 2.66 (1.53–4.63)c 0.001 2.40 (1.37–4.21) 0.002 1.96 (1.05–3.66) 0.034
Log soluble thrombomodulin 30.72 (8.37–112.67) < 0.001 29.55 (7.87–110.89) < 0.001 12.71 (2.96–54.67) 0.001
Log Syndecan‑1 1.98 (1.15–3.42) 0.014 1.90 (1.10–3.30) 0.022 1.49 (0.80–2.77) 0.212
Log vascular adhesion protein 1 1.07 (0.40–2.88) 0.891 1.66 (0.59–4.71) 0.340 0.93 (0.28–3.07) 0.907
Biomarker summary  scorec
Score-patients with AKI no/
total to (%)
Unadjusted OR (95% CI) p value IL-6  adjusteda OR (95% CI) p value Multivariable 
 adjustedb OR (95% 
CI)
p value
0–36/195 (18.5%) Reference – Reference – Reference –
1–32/121 (26.4%) 1.59 (0.92–2.73) 0.095 1.47 (0.85–2.54) 0.169 1.50 (0.83–2.70) 0.176
2–28/72 (38.9%) 2.81 (1.55–5.10) 0.001 2.73 (1.49–4.97) 0.001 2.11 (1.09–4.11) 0.027
3–16/27 (59.3%) 6.42 (2.75–15.01) < 0.001 5.96 (2.53–14.03) < 0.001 4.24 (1.64–10.96) 0.003
Table 5 Biomarker levels in all patients and according to 90-day mortality
Biomarker level (ng/mL) at 0 h 
(median [IQR])
All patients (n = 619) 90-day survivors (n = 439) 90-day non-survivors (n = 180) p value
Syndecan‑1 109.00 [62.30–215.40] 98.10 [58.40–180.00] 157.05 [72.50–310.80] < 0.001
Angiopoietin‑2 6.31 [3.39–12.13] 5.92 [3.30–11.26] 7.60 [4.01–17.44] 0.013
Soluble thrombomodulin 5.30 [4.02–7.13] 5.08 [3.88–6.81] 5.90 [4.37–8.19] < 0.001
Vascular adhesion protein‑1 241.00 [171.00–340.00] 239.00 [171.00–339.00] 253.00 [168.25–340.00] 0.676
Interleukin‑6 0.57 [0.14–4.74] 0.54 [0.13–4.25] 0.67 [0.15–6.51] 0.147
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fluid administration and severity of illness. However, the 
transmembrane form of VAP-1 facilitates leukocyte roll-
ing and transmigration, whereas the soluble form acts as 
a primary serum amine oxidase [28]. Possibly, in the most 
severely ill septic patients, the shedding of transmem-
brane form of VAP-1 into soluble form is reduced due to 
greater needs of the transmembrane form. Moreover, the 
plasma levels do not necessarily reflect the tissue levels 
of a biomarker. Finally, dilution of VAP-1 with increasing 
fluid balance cannot be excluded.
sTM was independently associated with the develop-
ment of AKI, as in a recent retrospective observational 
study among 514 septic patients [29] and a multicenter 
prospective observational study among 80 ICU patients 
[30]. Moreover, we demonstrated that an increase in sTM 
levels occurred already before AKI onset, unlike in the 
largest previous study [29]. Interestingly, we found Ang-2 
to be significantly associated with AKI in the univariate 
analysis but not in the adjusted model. A previous study 
reported an unadjusted association of AKI defined by 
the KDIGO creatinine criterion and Ang-2 levels [24]. 
Higher SDC-1 values have been previously observed 
to be associated with AKI in a study among 175 septic 
patients [31]. Albeit the SDC-1 levels in this study were 
higher among  AKI>12 h patients, SDC-1 was not indepen-
dently associated with AKI.
Our study corroborates previous results on the asso-
ciations between higher SDC-1, Ang-2 and sTM plasma 
levels and the severity of critical illness and mortality [9, 
22, 25, 31–33]. A multicenter trial in acute respiratory 
distress syndrome (ARDS) patients reported a positive 
correlation between sTM plasma levels and mortality, 
but found no difference in sTM levels between conserva-
tive and liberal fluid management groups [34]. Moreover, 
a recent study comparing early goal-directed therapy, 
standard therapy, and protocolized therapy found no 
difference in endothelial injury biomarkers including 
sTM and Ang-2 between the treatment arms, but higher 
Ang-2 and STM plasma levels were associated with 
60-day mortality [32]. We found an independent associa-
tion between Ang-2, sTM, and SDC-1 and 90-day mor-
tality. Moreover, patients who had high levels of all these 
three markers had a fivefold adjusted OR for 90-day mor-
tality compared to those in whom all these markers were 
low.
Given the multiple roles of the glycocalyx and 
endothelium in regulating vascular permeability and 
leukocyte adhesion [1–4], our results on increased mor-
tality are biologically plausible. A recent animal study 
Table 6 Unadjusted and adjusted single and multivariable biomarker models for 90-day mortality
Hosmer–Lemeshow test non-significant in all analyses
IL-6 interleukin-6
a Adjusted for log-transformed interleukin-6 value at ICU admission
b Adjusted for age, sex, body mass index, pre-existing arteriosclerosis, chronic heart failure, chronic kidney disease, diabetes mellitus, chronic corticosteroid use, 
operative admission, skin or soft tissue infection, central nervous system infection, other infection source, need for vasoactive medication within first 24 h, Simplified 
Acute Physiology Score (SAPS) II without points for age and renal components, first lactate in ICU, acute kidney injury within first 5 days in the ICU, fluid accumulation 
percentage of baseline weight within first 5 days in ICU, mechanical ventilation during ICU stay, and log-transformed interleukin-6 value at ICU admission. Total 
number of patients in the model was 619
c Including Angiopoietin-2, soluble thrombomodulin and Syndecan-1, each value in the highest tertile for each biomarker yielding a subscore of 1
Single biomarker models
Biomarker Unadjusted OR (95% CI) p value IL-6  adjusteda OR (95% CI) p value Multivariable 
 adjustedb OR (95% 
CI)
p value
Log Angiopoietin‑2 1.69 (1.12–2.55) 0.012 1.57 (1.03–2.38) 0.035 2.47 (1.44–4.14) 0.001
Log soluble thrombomodulin 2.36 (1.58–3.53) < 0.001 2.27 (1.52–3.40) < 0.001 7.35 (2.29–23.57) 0.001
Log Syndecan‑1 6.45 (2.58–16.09) < 0.001 5.94 (2.36–14.91) < 0.001 2.13 (1.31–3.49) 0.002
Log vascular adhesion protein 1 0.99 (0.47–2.09) 0.980 1.26 (0.58–2.75) 0.565 2.02 (0.73–5.57) 0.177
Biomarker summary  scorea
Score-90-day non-survivors 
no/total to (%)
Unadjusted OR (95% CI) p value IL-6  adjusteda OR (95% CI) p value Multivariable 
 adjustedb OR (95% 
CI)
p value
0–57/249 (22.9%) Reference – Reference – Reference –
1–49/187 (26.2%) 1.20 (0.77–1.86) 0.425 1.17 (0.75–1.81) 0.500 1.19 (0.70–2.01) 0.530
2–39/118 (33.1%) 1.66 (1.03–2.70) 0.040 1.60 (0.98–2.61) 0.058 1.93 (1.07–3.47) 0.029
3–35/65 (53.8%) 3.93 (2.22–6.95) < 0.001 3.69 (2.07–6.57) < 0.001 5.61 (2.67–11.79) < 0.001
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in experimental sepsis found fluid resuscitation (com-
pared to no resuscitation) to increase atrial natriuretic 
peptide (ANP) levels and lead to glycocalyx injury [35]. 
Furthermore, fluid resuscitation group exhibited higher 
vasopressor requirements, potentially due to glycoca-
lyx damage [35]. Additionally, hypervolemia has been 
found to increase glycocalyx shedding in an experimen-
tal volume loading study in surgical patients [36]. Taken 
together, these data suggest that some of the typical 
interventions used in sepsis resuscitation may aggravate 
glycocalyx and endothelial injury. Our results add to 
the increasing body of evidence highlighting the impor-
tance of endothelial and glycocalyx injury in the pathway 
of adverse outcomes and call for studies assessing novel 
means in avoiding and alleviating injury to endothelium 
and glycocalyx.
Our study has some strengths and limitations. This 
was a post hoc study from a large prospective multi-
center study with good generalizability to other critically 
ill septic patient cohorts. Moreover, we used the full set 
of KDIGO AKI criteria, and collected detailed and com-
prehensive data about clinical variables and risk factors 
for AKI. Most of the previous studies have used only the 
creatinine criterion for AKI [22–24, 31]. As a limitation, 
first, our study collected data about fluid administration 
and balance in 24-h blocks, which may not be granular 
enough to distinguish the fluid resuscitation phase. How-
ever, we extracted the fluid administration data of 44 
patients in 12-h blocks from the ICU data management 
system as a sensitivity analysis, and found it to correlate 
well with the ICU admission day fluid administration nor-
malized to the duration of observation period. Second, 
we did not have data regarding the pre-ICU fluid ther-
apy, which may have affected plasma biomarker levels at 
ICU admission and may explain why we could not show 
a connection between other biomarkers than VAP-1 and 
IL-6 and fluid load. However, some studies have suffered 
from the same limitation [25]. Third, we had to exclude 
36 deceased patients from the analysis because of absent 
consent. Nevertheless, percentage of these patients of the 
cohort was low (5.5%), and thus, unlikely to cause signifi-
cant bias. Fourth, this study was observational and had no 
protocol concerning hemodynamic monitoring or fluid 
responsiveness. Therefore, hemodynamic monitoring 
was performed and fluids were administered according 
to the treating clinician and standards of each participat-
ing ICU following the Surviving Sepsis Guidelines [13] in 
place that time. Fifth, we defined sepsis according to the 
American College of Chest Physicians/Society of Criti-
cal Care Medicine (ACCP/SCCM) definition [14]. Due to 
the structure of data collection, classifying patients ret-
rospectively according to the sepsis-3 definition was not 
possible. Sixth, fluid balance was calculated with inputs 
and outputs since weighting of all study participants was 
not possible. However, it is not obvious that regular body 
weight measures would be more precise to estimate fluid 
balance than fluid balance calculations [37]. Seventh, 
we used data-driven approach supplemented with clini-
cal discretion in selecting confounders for the logistic 
regression analyses, albeit a propensity score analysis 
might have been able to mitigate confounding better [38]. 
Finally, some unknown confounders might have been 
missing.
Conclusions
We found VAP-1 and IL-6, but not the other markers, to 
be associated with fluid administration on the first ICU 
day. Supporting previous results, sTM was independently 
associated with the development of AKI. Finally, Ang-2, 
sTM, and SDC-1 were independently associated with an 
increased risk for 90-day mortality. These findings sup-
port the importance of endothelial injury in the patho-
physiology of sepsis-associated AKI and highlight the 
role of the glycocalyx and endothelium in the pathway of 
adverse outcomes.
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